跳轉至內容
Merck
  • Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.

Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.

Clinical pharmacology in drug development (2017-03-17)
Susanne Johansson, David P Rosenbaum, Marie Ahlqvist, Helen Rollison, Mikael Knutsson, Bergur Stefansson, Marie Elebring
摘要

Tenapanor (RDX5791, AZD1722) is an inhibitor of sodium/hydrogen exchanger isoform 3 in development for the treatment of constipation-predominant irritable bowel syndrome and the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. We aimed to investigate whether tenapanor inhibits or induces cytochrome P450s (CYPs). In vitro experiments assessing the potential of tenapanor to affect various CYPs indicated that it could inhibit CYP3A4/5 (IC

材料
產品編號
品牌
產品描述

Sigma-Aldrich
CITCO, ≥98% (HPLC), solid